Investigadores
Inicio
Investigadores
Instituto de Investigaciones Biomédicas August Pi Sunyer (IDIBAPS). Barcelona.
Inmunoterapia Celular (células CAR)
Terapia de células somáticas y medicina regenerativa
Desarrollos Tecnológicos y Terapéuticos
Aleix Prat Aparicio
Investigador principal
Grupo de Investigación: Instituto de Investigaciones Biomédicas August Pi Sunyer (IDIBAPS). Barcelona.
Alvaro Urbano Ispizua
Investigador principal
Grupo de Investigación: Instituto de Investigaciones Biomédicas August Pi Sunyer (IDIBAPS). Barcelona.
Josep M Canals Coll
Investigador principal
Grupo de Investigación: Instituto de Investigaciones Biomédicas August Pi Sunyer (IDIBAPS). Barcelona.
Aina Oliver Caldes
Investigador colaborador
Grupo de Investigación: Instituto de Investigaciones Biomédicas August Pi Sunyer (IDIBAPS). Barcelona.
Daniel Benítez Ribas
Investigador colaborador
Grupo de Investigación: Instituto de Investigaciones Biomédicas August Pi Sunyer (IDIBAPS). Barcelona.
Europa Azucena González Navarro
Investigador colaborador
Grupo de Investigación: Instituto de Investigaciones Biomédicas August Pi Sunyer (IDIBAPS). Barcelona.
Joan Cid Vidal
Investigador colaborador
Grupo de Investigación: Instituto de Investigaciones Biomédicas August Pi Sunyer (IDIBAPS). Barcelona.
Luis Gerardo Rodríguez Lobato
Investigador colaborador
Grupo de Investigación: Instituto de Investigaciones Biomédicas August Pi Sunyer (IDIBAPS). Barcelona.
Marta Cervera Sospedra
Investigador colaborador
Grupo de Investigación: Instituto de Investigaciones Biomédicas August Pi Sunyer (IDIBAPS). Barcelona.
Mireia Uribe Herranz
Investigador colaborador
Grupo de Investigación: Instituto de Investigaciones Biomédicas August Pi Sunyer (IDIBAPS). Barcelona.
Albarrán-Fernández V., Angelats L., Delgado J., Gros A., Urbano-Ispizua Á., Guedan S., Prat A.. Unlocking the potential of engineered immune cell therapy for solid tumors. Nature Communications. December 2025. DOI: 10.1038/s41467-025-56527-0.
Impacto: 14.7. Cuartil: Q1
(1er decil)
Molina-Ruiz F.J., Sanders P., Gomis C., Abante J., Londoño F., Bombau G., Galofré M., Vinyes-Bassols G.l., Monforte V., Canals J.M.. CD200-based cell sorting results in homogeneous transplantable striatal neuroblasts for human cell therapy for Huntington's disease. Neurobiology of Disease. 1 June 2025. DOI: 10.1016/j.nbd.2025.106905.
Impacto: 5.1. Cuartil: Q1
Merchán-Muñoz B., Suárez-Lledó M., Rodríguez-Lobato L.G., Aiello T.F., Gallardo-Pizarro A., Charry P., Cid J., Lozano M., Pedraza A., Martínez-Roca A., Guardia A., Guardia L., Moreno C., Carreras E., Rosiñol L., García-Vidal C., Fernández-Avilés F., Martínez C., Rovira M., Salas M.Q.. Post-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on Infectious Complications and Immune Reconstitution According to Donor Type. Cancers. April 2025. DOI: 10.3390/cancers17071109.
Impacto: 4.5. Cuartil: Q1
Guerrero-Murillo M., Rill-Hinarejos A., Trincado J.L., Bataller A., Ortiz-Maldonado V., Benítez-Ribas D., Español-Rego M., González-Navarro E.A., Martínez-Cibrián N., Marchese D., Martín-Martín L., García-Sancho A.M., Rives S., Heyn H., Juan M., Urbano-Ispizúa Á., Delgado J., Orfao A., Mereu E., Bueno C., Menendez P.. Erratum: Integrative single-cell multi-omics of CD19-CAR<sup>pos</sup> and CAR<sup>neg</sup> T cells suggest drivers of immunotherapy response in B cell neoplasias (Cell Reports Medicine (2024) 5(11), (S2666379124005500), (10.1016/j.xcrm.2024.101803)). Cell Reports Medicine. 18 March 2025. DOI: 10.1016/j.xcrm.2025.102026.
Impacto: 11.7. Cuartil: Q1
(1er decil)
Battram A.M., Mane-Pujol J., Moreno D.F., Oliver-Caldés A., Carpio J., Cardus O., Rodríguez-Lobato L.G., Urbano-Ispizua Á., de Larrea C.F.. Genetic disruption of Blimp-1 drastically augments the antitumor efficacy of BCMA-targeting CAR T cells. Blood Advances. 11 February 2025. DOI: 10.1182/bloodadvances.2024013209.
Impacto: 7.4. Cuartil: Q1
Zugasti I., Tormo-Ratera M., Oliver-Caldés A., Soler-Perromat J.C., González-Calle V., Moreno D.F., Cabañas V., López-Muñoz N., Bartolomé-Solanas Á., Español-Rego M., Reguera-Ortega J.L., Rosiñol L., López-Corral L., Tovar N., Rodríguez-Lobato L.G., Alvarez Perez R.M., Varea S., Olesti E., Gomez-Grande A., Frutos L., Tamayo P., Juan M., Moraleda J.M., Urbano-Ispizua Á., González-Navarro E.A., Martínez-López J., Mateos M.V., Tomás X., Setoain X., Fernández de Larrea C.. Clinical impact of [<sup>18</sup>F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma. Blood Advances. 11 February 2025. DOI: 10.1182/bloodadvances.2024014360.
Impacto: 7.4. Cuartil: Q1
Bachiller M., Barceló-Genestar N., Rodriguez-Garcia A., Alserawan L., Dobaño-López C., Giménez-Alejandre M., Castellsagué J., Colell S., Otero-Mateo M., Antoñana-Vildosola A., Español-Rego M., Ferruz N., Pascal M., Martín-Antonio B., Anguela X.M., Fillat C., Olesti E., Calvo G., Juan M., Delgado J., Pérez-Galán P., Urbano-Ispizua Á., Guedan S.. ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma. Molecular Therapy. 8 January 2025. DOI: 10.1016/j.ymthe.2024.11.028.
Impacto: 12.1. Cuartil: Q1
(1er decil)
Zabaleta A., Puig N., Cedena M.T., Oliver-Caldes A., Perez J.J., Moreno C., Tamariz-Amador L.E., Rodriguez-Otero P., Prosper F., Gonzalez-Calle V., López-Corral L., Rey-Búa B., Puertas B., Mirás F., Sánchez-Pina J.M., López-Muñoz N., Juan M., González-Navarro E.A., Urbano Á., de Larrea C.F., Blade J., Lahuerta J.J., Martinez-Lopez J., Mateos M.V., San Miguel J.F., Paiva B.. Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy. American Journal of Hematology. January 2025. DOI: 10.1002/ajh.27526.
Impacto: 10.1. Cuartil: Q1
(1er decil)
Choque-Chávez F.D., Jareño-Badenas A., Benítez-Ribas D., Oleaga L.. Evaluation of central nervous system involvement in patients undergoing chimeric antigen receptor-engineered T-cell therapy by magnetic resonance imaging. Radiologia. 1 January 2025. DOI: 10.1016/j.rx.2023.09.002.
Merz M., Albici A.M., von Tresckow B., Rathje K., Fenk R., Holderried T., Müller F., Tovar N., Oliver-Cáldes A., Vucinic V., Kharboutli S., Bärmann B.N., Ayuk F., Platzbecker U., Stölzel F., Schub N., Schmitz F., Fandrei D., Born P., Khandanpour C., Hanoun C., Hörster K., Teichert M., Jeker B., Hoffmann M., Kröger N., de Larrea C.F., Pabst T., Gagelmann N.. Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study. HemaSphere. January 2025. DOI: 10.1002/hem3.70070.
Impacto: 7.6. Cuartil: Q1
Urbano-Ispizua Á., Shah N.N., Kekre N.. Point-of-care CAR T manufacturing solutions: can 1 model fit all?. Blood Advances. 10 December 2024. DOI: 10.1182/bloodadvances.2024012982.
Impacto: 7.4. Cuartil: Q1
Cibeira M.T., Rodríguez-Lobato L.G., Alejaldre A., de Larrea C.F.. Neurological manifestations of MGUS. Hematology (United States). 6 December 2024. DOI: 10.1182/hematology.2024000665.
Impacto: 2.9. Cuartil: Q1
Shen Y.R., Zaballa S., Bech X., Sancho-Balsells A., Rodríguez-Navarro I., Cifuentes-Díaz C., Seyit-Bremer G., Chun S.H., Straub T., Abante J., Merino-Valverde I., Richart L., Gupta V., Li H.Y., Ballasch I., Alcázar N., Alberch J., Canals J.M., Abad M., Serrano M., Klein R., Giralt A., del Toro D.. Expansion of the neocortex and protection from neurodegeneration by in vivo transient reprogramming. Cell Stem Cell. 5 December 2024. DOI: 10.1016/j.stem.2024.09.013.
Impacto: 19.8. Cuartil: Q1
(1er decil)
Salas M.Q., Rodríguez-Lobato L.G., Charry P., Suárez-Lledó M., Pedraza A., Solano M.T., Arcarons J., Cid J., Lozano M., Rosiñol L., Esteve J., Carreras E., Fernández-Avilés F., Martínez C., Rovira M.. Applicability and validation of different prognostic scores in allogeneic hematopoietic cell transplant (HCT) in the post-transplant cyclophosphamide era. Hematology, Transfusion and Cell Therapy. December 2024. DOI: 10.1016/j.htct.2023.07.008.
Andreu-Saumell I., Rodriguez-Garcia A., Mühlgrabner V., Gimenez-Alejandre M., Marzal B., Castellsagué J., Brasó-Maristany F., Calderon H., Angelats L., Colell S., Nuding M., Soria-Castellano M., Barbao P., Prat A., Urbano-Ispizua A., Huppa J.B., Guedan S.. CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition. Nature Communications. December 2024. DOI: 10.1038/s41467-024-47799-z.
Impacto: 14.7. Cuartil: Q1
(1er decil)
Merz M., Dima D., Hashmi H., Ahmed N., Stölzel F., Holderried T.A.W., Fenk R., Müller F., Tovar N., Oliver-Cáldes A., Rathje K., Davis J.A., Fandrei D., Vucinic V., Kharboutli S., Baermann B.N., Ayuk F., Platzbecker U., Albici A.M., Schub N., Schmitz F., Shune L., Khouri J., Anwer F., Raza S., McGuirk J., Mahmoudjafari Z., Green K., Khandanpour C., Teichert M., Jeker B., Hoffmann M., Kröger N., von Tresckow B., de Larrea C.F., Pabst T., Abdallah A.O., Gagelmann N.. Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy. Blood Cancer Journal. December 2024. DOI: 10.1038/s41408-024-01197-2.
Impacto: 12.9. Cuartil: Q1
(1er decil)
Martinez-Verbo L., Veselinova Y., Llinàs-Arias P., García-Prieto C.A., Noguera-Castells A., Pato M.L., Bueno-Costa A., Campillo-Marcos I., Villanueva L., Oliver-Caldes A., Cardus O., Salsench S.V., García-Ortiz A., Valeri A., Rojas E.A., Barrena N., Gutiérrez N.C., Prósper F., Agirre X., Fernández de Larrea C., Martínez-López J., Ferrer G., Esteller M.. PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma. Leukemia. December 2024. DOI: 10.1038/s41375-024-02419-z.
Impacto: 12.8. Cuartil: Q1
(1er decil)
Ballasch I., López-Molina L., Galán-Ganga M., Sancho-Balsells A., Rodríguez-Navarro I., Borràs-Pernas S., Rabadan M.A., Chen W., Pastó-Pellicer C., Flotta F., Maoyu W., Fernández-Irigoyen J., Santamaría E., Aguilar R., Dobaño C., Egri N., Hernandez C., Alfonso M., Juan M., Alberch J., del Toro D., Arranz B., Canals J.M., Giralt A.. Alterations of the IKZF1-IKZF2 tandem in immune cells of schizophrenia patients regulate associated phenotypes. Journal of Neuroinflammation. December 2024. DOI: 10.1186/s12974-024-03320-3.
Impacto: 9.3. Cuartil: Q1
(1er decil)
Martínez-Roca A., Jiménez-Vicente C., Merchán B., Castaño-Diez S., Zugasti I., Brillembourg H., Bataller Á., Guijarro F., Cortés-Bullich A., Trigueros A., Pérez-Valencia A.I., Gallego C., Ballestar N., Rodríguez-Lobato L.G., Carcelero E., Díaz-Beyá M., Esteve J., Fernández-Avilés F.. At-Home Care Program for Acute Myeloid Leukemia Induction Phase in Patients Treated with Venetoclax-Based Low-Intensity Regimens. Cancers. December 2024. DOI: 10.3390/cancers16244274.
Impacto: 4.5. Cuartil: Q1
Guerrero-Murillo M., Rill-Hinarejos A., Trincado J.L., Bataller A., Ortiz-Maldonado V., Benítez-Ribas D., Español-Rego M., González-Navarro E.A., Martínez-Cibrián N., Marchese D., Martín-Martín L., Martín García-Sancho A., Rives S., Heyn H., Juan M., Urbano-Ispizúa Á., Delgado J., Orfao A., Mereu E., Bueno C., Menendez P.. Integrative single-cell multi-omics of CD19-CAR<sup>pos</sup> and CAR<sup>neg</sup> T cells suggest drivers of immunotherapy response in B cell neoplasias. Cell Reports Medicine. 19 November 2024. DOI: 10.1016/j.xcrm.2024.101803.
Impacto: 11.7. Cuartil: Q1
(1er decil)
Ortiz de Landazuri I., Oliver-Caldés A., Español-Rego M., Agulló C., Contreras M.T., Zabaleta A., Puig N., Cabañas V., González-Calle V., Zugasti I., Inogés S., Rodríguez Otero P., Martin-Antonio B., Reguera J.L., López-Diaz de Cerio A., Aróstegui J.I., Uribe-Herranz M., Benítez-Ribas D., Rodríguez-Lobato L.G., González E.A., Tovar N., Charry P., Navarro S., Rosiñol L., Tréboles K., Mora G., Yagüe J., Moraleda J.M., Urbano-Ispizua Á., Mateos M.V., Pascal M., Paiva B., Juan M., Fernández de Larrea C.. Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells. British Journal of Haematology. October 2024. DOI: 10.1111/bjh.19589.
Impacto: 5.1. Cuartil: Q1
Lozano E., Mena M.P., Garrabou G., Cardús O., Díaz T., Moreno D.F., Mañé-Pujol J., Oliver-Caldés A., Battram A., Tovar N., Cibeira M.T., Rodríguez-Lobato L.G., Bladé J., de Larrea C.F., Rosiñol L.. Increased PVR Expression on Bone Marrow Macrophages May Promote Resistance to TIGIT Blockade in Multiple Myeloma. Clinical Cancer Research. 1 September 2024. DOI: 10.1158/1078-0432.CCR-24-0117.
Impacto: 10.0. Cuartil: Q1
Juárez A., Salas M.Q., Pedraza A., Suárez-Lledó M., Rodríguez-Lobato L.G., Solano M.T., Serrahima A., Nomdedeu M., Cid J., Lozano M., Charry P., Arcarons J., Llobet N., Rosiñol L., Fernández-Avilés F., Rovira M., Martínez C.. Reduced Dose of Post-Transplant Cyclophosphamide with Tacrolimus for the Prevention of Graft-versus-Host Disease in HLA-Matched Donor Peripheral Blood Stem Cell Transplants: A Prospective Pilot Study. Cancers. July 2024. DOI: 10.3390/cancers16142567.
Impacto: 4.5. Cuartil: Q1
Delgado J., Juan M., Calvo G., Urbano-Ispizua Á.. The development of academic CAR T cells. The Lancet Haematology. July 2024. DOI: 10.1016/S2352-3026(24)00170-4.
Impacto: 15.4. Cuartil: Q1
(1er decil)
Escribano-Serrat S., Rodríguez-Lobato L.G., Suárez-Lledó M., Pedraza A., Charry P., Cid J., Lozano M., Esteve J., Rosiñol L., Fernández-Avilés F., Carreras E., Díaz-Ricart M., Martínez C., Rovira M., Salas M.Q.. Improving the EASIX’ predictive power for NRM in adults undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. July 2024. DOI: 10.1038/s41409-024-02267-6.
Impacto: 4.5. Cuartil: Q1
Jiménez-Vicente C., Charry P., Castaño-Diez S., Guijarro F., López-Guerra M., Pérez-Valencia A.I., Martinez-Roca A., Cortés-Bullich A., Munárriz D., Solano M.T., Rosiñol L., Carreras E., Urbano-Ispizua Á., Fernández-Avilés F., Martinez C., Suárez-Lledó M., Díaz-Beyá M., Rovira M., Salas M.Q., Esteve J.. Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group. British Journal of Haematology. July 2024. DOI: 10.1111/bjh.19518.
Impacto: 5.1. Cuartil: Q1
Tolosa-Ridao C., Cascos E., Rodríguez-Lobato L.G., Pedraza A., Suárez-Lledó M., Charry P., Solano M.T., Martinez-Sanchez J., Cid J., Lozano M., Rosiñol L., Esteve J., Urbano-Ispizua Á., Fernández-Avilés F., Martínez C., Carreras E., Díaz-Ricart M., Rovira M., Salas M.Q.. EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. July 2024. DOI: 10.1038/s41409-024-02270-x.
Impacto: 4.5. Cuartil: Q1
Oliver-Caldes A., Español-Rego M., Zabaleta A., González-Calle V., Navarro-Velázquez S., Inogés S., López-Díaz de Cerio A., Cabañas V., López-Muñoz N., Rodríguez-Otero P., Reguera J.L., Moreno D.F., Martínez-Cibrian N., López-Corral L., Pérez-Amill L., Martin-Antonio B., Rosiñol L., Cid J., Tovar N., Sáez-Peñataro J., López-Parra M., Olesti E., Guillén E., Varea S., Rodríguez-Lobato L.G., Battram A.M., González M.S., Sánchez-Salinas A., González-Navarro A., Ortiz-Maldonado V., Delgado J., Prósper F., Juan M., Martínez-López J., Moraleda J.M., Mateos M.V., Urbano-Ispizua Á., Paiva B., Pascal M., de Larrea C.F.. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma. Clinical Cancer Research. 15 May 2024. DOI: 10.1158/1078-0432.CCR-23-3759.
Impacto: 10.0. Cuartil: Q1
Gagelmann N., Dima D., Merz M., Hashmi H., Ahmed N., Tovar N., Oliver-Caldés A., Stölzel F., Rathje K., Fischer L., Born P., Schäfer L., Albici A.M., Schub N., Kfir-Erenfeld S., Assayag M., Asherie N., Wulf G.G., Kharboutli S., Müller F., Shune L., Davis J.A., Anwer F., Vucinic V., Platzbecker U., Ayuk F., Kröger N., Khouri J., Gurnari C., McGuirk J., Stepensky P., Abdallah A.O., Fernández De Larrea C.. Development and Validation of a Prediction Model of Outcome after B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology. 10 May 2024. DOI: 10.1200/JCO.23.02232.
Impacto: 42.1. Cuartil: Q1
(1er decil)
de Daniel A., Rodríguez-Lobato L.G., Tovar N., Cibeira M.T., Moreno D.F., Oliver-Caldés A., Isola I., Lozano E., Bladé J., Rosiñol L., Fernández de Larrea C.. The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma. HemaSphere. May 2024. DOI: 10.1002/hem3.76.
Impacto: 7.6. Cuartil: Q1
Comoli P., Pentheroudakis G., Ruggeri A., Koehl U., Lordick F., Mooyaart J.E., Hoogenboom J.D., Urbano-Ispizua A., Peters S., Kuball J., Kröger N., Sureda A., Chabannon C., Haanen J., Pedrazzoli P.. Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey. Annals of Oncology. April 2024. DOI: 10.1016/j.annonc.2023.12.009.
Impacto: 56.7. Cuartil: Q1
(1er decil)
Garcia-Pouton N., Ortiz-Maldonado V., Peyrony O., Chumbita M., Aiello T.F., Monzo-Gallo P., Lopera C., Puerta-Alcalde P., Magnano L., Martinez-Cibrian N., Pitart C., Juan M., Delgado J., Fernandez De Larrea C., Soriano Á., Urbano-Ispizua Á., Garcia-Vidal C.. Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy. European Journal of Haematology. March 2024. DOI: 10.1111/ejh.14122.
Impacto: 2.3. Cuartil: Q2
Pedraza A., Salas M.Q., Rodríguez-Lobato L.G., Escribano-Serrat S., Suárez-Lledo M., Martínez-Cebrian N., Solano M.T., Arcarons J., Rosiñol L., Gutiérrez-García G., Fernández-Avilés F., Moreno-Castaño A.B., Molina P., Pino M., Carreras E., Díaz-Ricart M., Rovira M., Palomo M., Martínez C.. Easix Score Correlates With Endothelial Dysfunction Biomarkers and Predicts Risk of Acute Graft-Versus-Host Disease After Allogeneic Transplantation. Transplantation and Cellular Therapy. February 2024. DOI: 10.1016/j.jtct.2023.11.016.
Impacto: 3.6. Cuartil: Q1
Martínez-Cibrián N., Ortiz-Maldonado V., Español-Rego M., Blázquez A., Cid J., Lozano M., Magnano L., Giné E., Correa J.G., Mozas P., Rodríguez-Lobato L.G., Rivero A., Montoro-Lorite M., Ayora P., Navarro S., Alserawan L., González-Navarro E.A., Castellà M., Sánchez-Castañón M., Cabezón R., Benítez-Ribas D., Setoaín X., Rodríguez S., Brillembourg H., Varea S., Olesti E., Guillén E., Sáez-Peñataro J., de Larrea C.F., López-Guillermo A., Pascal M., Urbano-Ispizua Á., Juan M., Delgado J.. The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. British Journal of Haematology. February 2024. DOI: 10.1111/bjh.19170.
Impacto: 5.1. Cuartil: Q1
Salas M.Q., Pedraza A., Charry P., Suárez-Lledó M., Rodríguez-Lobato L.G., Brusosa M., Solano M.T., Serrahima A., Nomdedeu M., Cid J., Lozano M., Arcarons J., de Llobet N., Rosiñol L., Esteve J., Urbano-Ispizua Á., Carreras E., Fernández-Avilés F., Rovira M., Martinez C.. Post-Transplantation Cyclophosphamide and Tacrolimus for Graft-versus-Host Disease Prevention after Allogeneic Hematopoietic Cell Transplantation from HLA-Matched Donors Has More Advantages Than Limitations. Transplantation and Cellular Therapy. February 2024. DOI: 10.1016/j.jtct.2023.11.020.
Impacto: 3.6. Cuartil: Q1
Escribano-Serrat S., Rodríguez-Lobato L.G., Charry P., Martínez-Cibrian N., Suárez-Lledó M., Rivero A., Moreno-Castaño A.B., Solano M.T., Arcarons J., Nomdedeu M., Cid J., Lozano M., Pedraza A., Rosiñol L., Esteve J., Urbano-Ispizua Á., Palomo M., Fernández-Avilés F., Martínez C., Díaz-Ricart M., Carreras E., Rovira M., Salas M.Q.. Endothelial Activation and Stress Index in adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based prophylaxis. Cytotherapy. January 2024. DOI: 10.1016/j.jcyt.2023.10.008.
Impacto: 3.7. Cuartil: Q1
Sancho-Balsells A., Brito V., Fernández B., Pardo M., Straccia M., Ginés S., Alberch J., Hernández I., Arranz B., Canals J.M., Giralt A.. Corrigendum: Lack of Helios during neural development induces adult schizophrenia-like behaviors associated with aberrant levels of the TRIF-recruiter protein WDFY1 (Frontiers in Cellular Neuroscience, (2020), 14, (93), 10.3389/fncel.2020.00093). Frontiers in Cellular Neuroscience. 2024. DOI: 10.3389/fncel.2024.1542681.
Impacto: 4.2. Cuartil: Q2
Ruiz-Boy S., Pedraza A., Prat M., Salas M.Q., Carcelero E., Riu-Viladoms G., Suárez-Lledó M., Monge-Escartín I., Rodríguez-Lobato L.G., Martínez-Roca A., Rovira M., Martínez C., Gallego C., Urbano-Ispizua Á., Sánchez J., Marcos M.Á., Fernández-Avilés F.. At-Home Foscarnet Administration in Patients with Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation: A Unicentric, Safe, and Feasible Program. Pharmaceuticals. December 2023. DOI: 10.3390/ph16121741.
Impacto: 4.3. Cuartil: Q1
Rodríguez-Lobato L.G., Tovar N., de Daniel A., Fernández de Larrea C., Cibeira M.T., Jiménez-Segura R., Moreno D.F., Oliver-Caldés A., Bladé J., Rosiñol L.. Outcomes of Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma According to Clinical Trials Enrollment: Experience of a Single Institution. Cancers. November 2023. DOI: 10.3390/cancers15215261.
Impacto: 4.5. Cuartil: Q1
Perales-Linares R., Leli N.M., Mohei H., Beghi S., Rivera O.D., Kostopoulos N., Giglio A., George S.S., Uribe-Herranz M., Costabile F., Pierini S., Pustylnikov S., Skoufos G., Barash Y., Hatzigeorgiou A.G., Koumenis C., Maity A., Lotze M.T., Facciabene A.. Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance. Cancer Research. 1 November 2023. DOI: 10.1158/0008-5472.CAN-22-2499.
Impacto: 12.5. Cuartil: Q1
(1er decil)
Avivi I., Vesole D.H., Davila-Valls J., Usnarska-Zubkiewicz L., Olszewska-Szopa M., Milunovic V., Baumert B., Osękowska B., Kopińska A., Gentile M., Puertas-Martinez B., Robak P., Crusoe E., Rodriguez-Lobato L.G., Gajewska M., Varga G., Delforge M., Cohen Y., Gozzetti A., Pena C., Shustik C., Mikala G., Zalac K., Alexander H.D., Barth P., Weisel K., Martínez-López J., Waszczuk-Gajda A., Krzystański M., Jurczyszyn A.. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients. Cancers. September 2023. DOI: 10.3390/cancers15174359.
Impacto: 4.5. Cuartil: Q1
Oliver-Caldés A., González-Calle V., Cabañas V., Español-Rego M., Rodríguez-Otero P., Reguera J.L., López-Corral L., Martin-Antonio B., Zabaleta A., Inogés S., Varea S., Rosiñol L., López-Díaz de Cerio A., Tovar N., Jiménez R., López-Parra M., Rodríguez-Lobato L.G., Sánchez-Salinas A., Olesti E., Calvo-Orteu M., Delgado J., Pérez-Simón J.A., Paiva B., Prósper F., Sáez-Peñataro J., Juan M., Moraleda J.M., Mateos M.V., Pascal M., Urbano-Ispizua A., Fernández de Larrea C.. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. The Lancet Oncology. August 2023. DOI: 10.1016/S1470-2045(23)00222-X.
Impacto: 41.6. Cuartil: Q1
(1er decil)
Miguez A., Gomis C., Vila C., Monguió-Tortajada M., Fernández-García S., Bombau G., Galofré M., García-Bravo M., Sanders P., Fernández-Medina H., Poquet B., Salado-Manzano C., Roura S., Alberch J., Segovia J.C., Allen N.D., Borràs F.E., Canals J.M.. Soluble mutant huntingtin drives early human pathogenesis in Huntington’s disease. Cellular and Molecular Life Sciences. August 2023. DOI: 10.1007/s00018-023-04882-w.
Impacto: 6.2. Cuartil: Q1
Weiss L., Weiden J., Dölen Y., Grad E.M., van Dinther E.A.W., Schluck M., Eggermont L.J., van Mierlo G., Gileadi U., Bartoló-Ibars A., Raavé R., Gorris M.A.J., Maassen L., Verrijp K., Valente M., Deplancke B., Verdoes M., Benitez-Ribas D., Heskamp S., van Spriel A.B., Figdor C.G., Hammink R.. Direct In Vivo Activation of T Cells with Nanosized Immunofilaments Inhibits Tumor Growth and Metastasis. ACS Nano. 11 July 2023. DOI: 10.1021/acsnano.2c11884.
Impacto: 15.8. Cuartil: Q1
(1er decil)
Sánchez-Guijo F., Avendaño-Solá C., Badimón L., Bueren J.A., Canals J.M., Delgadillo J., Delgado J., Eguizábal C., Fernández-Santos M.E., García-Olmo D., González-Aseguinolaza G., Juan M., Martín F., Mata R., Montserrat N., Pérez-Martínez A., Pérez-Simón J.A., Prósper F., Urbano-Ispizua Á., Zapata A.G., Sureda A., Moraleda J.M.. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV). Bone Marrow Transplantation. June 2023. DOI: 10.1038/s41409-023-01962-0.
Impacto: 4.5. Cuartil: Q1
Pérez-Valencia A.I., Cascos E., Carbonell-Ordeig S., Charry P., Gómez-Hernando M., Rodríguez-Lobato L.G., Suárez-Lledó M., Martínez-Cibrian N., Antelo M.G., Solano M.T., Arcarons J., Nomdedeu M., Cid J., Lozano M., Díaz-Ricart M., Rosiñol L., Esteve J., Urbano-Ispizua Á., Carreras E., Martínez C., Fernández-Avilés F., Rovira M., Salas M.Q.. Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant. Blood Advances. 23 May 2023. DOI: 10.1182/bloodadvances.2022008792.
Impacto: 7.4. Cuartil: Q1
Moreno-Castaño A.B., Fernández S., Ventosa H., Palomo M., Martinez-Sanchez J., Ramos A., Ortiz-Maldonado V., Delgado J., Fernández De Larrea C., Urbano-Ispizua A., Penack O., Nicolás J.M., Téllez A., Escolar G., Carreras E., Fernández-Avilés F., Castro P., Diaz-Ricart M.. Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: Laboratory tools for an early and differential diagnosis. Journal for ImmunoTherapy of Cancer. 12 April 2023. DOI: 10.1136/jitc-2022-006365.
Impacto: 10.3. Cuartil: Q1
(1er decil)
Español-Rego M., Fernández-Martos C., Elez E., Foguet C., Pedrosa L., Rodríguez N., Ruiz-Casado A., Pineda E., Cid J., Cabezón R., Oliveres H., Lozano M., Ginés A., García-Criado A., Ayuso J.R., Pagés M., Cuatrecasas M., Torres F., Thomson T., Cascante M., Benítez-Ribas D., Maurel J.. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study. Cancer Immunology, Immunotherapy. April 2023. DOI: 10.1007/s00262-022-03283-5.
Impacto: 4.6. Cuartil: Q1
Uribe-Herranz M., Beghi S., Ruella M., Parvathaneni K., Salaris S., Kostopoulos N., George S.S., Pierini S., Krimitza E., Costabile F., Ghilardi G., Amelsberg K.V., Lee Y.G., Pajarillo R., Markmann C., McGettigan-Croce B., Agarwal D., Frey N., Lacey S.F., Scholler J., Gabunia K., Wu G., Chong E., Porter D.L., June C.H., Schuster S.J., Bhoj V., Facciabene A.. Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy. Molecular Therapy. 1 March 2023. DOI: 10.1016/j.ymthe.2023.01.012.
Impacto: 12.1. Cuartil: Q1
(1er decil)
Pedraza A., Salas M.Q., Rodríguez-Lobato L.G., Charry P., Suárez-Lledo M., Martínez-Cibrian N., Doménech A., Solano M.T., Arcarons J., de Llobet N., Rosiñol L., Gutiérrez-García G., Avilés F.F., Urbano-Ispízua Á., Rovira M., Martínez C.. Effect of CD34<sup>+</sup> Cell Dose on the Outcomes of Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy. March 2023. DOI: 10.1016/j.jtct.2022.12.005.
Impacto: 3.6. Cuartil: Q1
Piñeyroa J.A., Cid J., Vlagea A., Carbassé G., Henao P., Bailo N., Ortiz-Maldonado V., Martínez-Cibrian N., Español M., Delgado J., Urbano-Ispizua Á., Lozano M.. Evaluation of cell collection efficiency in non-mobilized adult donors for autologous chimeric antigen receptor T-cell manufacturing. Vox Sanguinis. March 2023. DOI: 10.1111/vox.13394.
Impacto: 1.8. Cuartil: Q3
Ballasch I., García-García E., Vila C., Pérez-González A., Sancho-Balsells A., Fernández J., Soto D., Puigdellívol M., Gasull X., Alberch J., Rodríguez M.J., Canals J.M., Giralt A.. Ikzf1 as a novel regulator of microglial homeostasis in inflammation and neurodegeneration. Brain, Behavior, and Immunity. March 2023. DOI: 10.1016/j.bbi.2023.01.016.
Impacto: 8.8. Cuartil: Q1
(1er decil)
García-Guerrero E., Rodríguez-Lobato L.G., Sierro-Martínez B., Danhof S., Bates S., Frenz S., Haertle L., Götz R., Sauer M., Rasche L., Kortüm K.M., Pérez-Simón J.A., Einsele H., Hudecek M., Prommersberger S.R.. All-trans retinoic acid works synergistically with the γsecretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells. Haematologica. February 2023. DOI: 10.3324/haematol.2022.281339.
Impacto: 8.2. Cuartil: Q1
Gómez-Hernando M., Quintana L.F., Suárez-Lledo M., Martínez-Cibrian N., Rivero A., Ruiz-Boy S., Carcelero E., Mate P., Riu G., Monge I., Serrahima A., Solano M.T., Rosiñol L., Esteve J., Urbano-Ispizua A., Carreras E., Fernández-Avilés F., Martínez C., Rovira M., Salas M.Q.. Hyponatremia induced by post-transplant cyclophosphamide in allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. February 2023. DOI: 10.1038/s41409-022-01864-7.
Impacto: 4.5. Cuartil: Q1
González-Brito A., Uribe-Herranz M.. The potential role of short chain fatty acids improving ex vivo T and CAR-T cell fitness and expansion for cancer immunotherapies. Frontiers in Immunology. 20 January 2023. DOI: 10.3389/fimmu.2023.1083303.
Impacto: 5.7. Cuartil: Q1
Pereira I., Lopez-Martinez M.J., Villasante A., Introna C., Tornero D., Canals J.M., Samitier J.. Hyaluronic acid-based bioink improves the differentiation and network formation of neural progenitor cells. Frontiers in Bioengineering and Biotechnology. 2023. DOI: 10.3389/fbioe.2023.1110547.
Impacto: 4.3. Cuartil: Q1
Moreno D.F., López-Guerra M., Paz S., Oliver-Caldés A., Mena M.P., Correa J.G., Battram A.M., Osuna M., Rivas-Delgado A., Rodríguez-Lobato L.G., Cardús O., Tovar N., Cibeira M.T., Jiménez-Segura R., Bladé J., Rosiñol L., Colomer D., Fernández de Larrea C.. Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia. British Journal of Haematology. January 2023. DOI: 10.1111/bjh.18502.
Impacto: 5.1. Cuartil: Q1
Bonelli J., Velasco-de Andrés M., Isidro N., Bayó C., Chumillas S., Carrillo-Serradell L., Casadó-Llombart S., Mok C., Benítez-Ribas D., Lozano F., Rocas J., Marchán V.. Novel Tumor-Targeted Self-Nanostructured and Compartmentalized Water-in-Oil-in-Water Polyurethane-Polyurea Nanocapsules for Cancer Theragnosis. Pharmaceutics. January 2023. DOI: 10.3390/pharmaceutics15010058.
Impacto: 4.9. Cuartil: Q1
Nogués-Castell J., Feu-Basilio S., Felguera García Ó., Fernández de Larrea C., Oliver-Caldés A., Balagué Ponz O., Fassi J.M.. Bilateral orbital plasmacytomas as first sign of extramedullary progression post CAR-T therapy: case report and literature review. Frontiers in Oncology. 2023. DOI: 10.3389/fonc.2023.1217714.
Impacto: 3.5. Cuartil: Q2
Marco D.N., Salas M.Q., Gutiérrez-García G., Monge I., Riu G., Carcelero E., Roma J.R., Llobet N., Arcarons J., Suárez-Lledó M., Martínez N., Pedraza A., Domenech A., Rosiñol L., Fernández-Avilés F., Urbano-Ispízua Á., Rovira M., Brunet M., Martínez C.. Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide. Pharmaceuticals. December 2022. DOI: 10.3390/ph15121529.
Canals J., Navarro A., Vila C., Canals J.M., Díaz T., Acosta-Plasencia M., Cros-Font C., Han B., He Y., Monzó M.. Human embryonic mesenchymal lung-conditioned medium promotes differentiation to myofibroblast and loss of stemness phenotype in lung adenocarcinoma cell lines. Journal of Experimental and Clinical Cancer Research. December 2022. DOI: 10.1186/s13046-021-02206-z.
Impacto: 11.3. Cuartil: Q1
Salas M.Q., Charry P., Puerta-Alcalde P., Martínez-Cibrian N., Solano M.T., Serrahima A., Nomdedeu M., Cid J., Lozano M., Chumbinta M., Aiello T.F., Arcarons J., LLobet N.d., Pedraza A., Rosiñol L., Esteve J., Urbano-Ispizua Á., Carreras E., Martínez C., Fernández-Avilés F., García-Vidal C., Suárez-Lledó M., Rovira M.. Bacterial Bloodstream Infections in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy. December 2022. DOI: 10.1016/j.jtct.2022.09.001.
Impacto: 3.2. Cuartil: Q2
Oliver-Caldes A., Jiménez R., Español-Rego M.. Erratum: First report of CART treatment in AL Amyloidosis and relapsed/refractory multiple myeloma (J Immunother Cancer (2021) 9 (e003783) DOI: 10.1136/jitc-2021-003783). Journal for ImmunoTherapy of Cancer. 3 November 2022. DOI: 10.1136/jitc-2021-003783corr1.
Rodriguez-Marquez P., Calleja-Cervantes M.E., Serrano G., Oliver-Caldes A., Palacios-Berraquero M.L., Martin-Mallo A., Calviño C., Español-Rego M., Ceballos C., Lozano T., Martin-Uriz P.S., Vilas-Zornoza A., Rodriguez-Diaz S., Martinez-Turrillas R., Jauregui P., Alignani D., Viguria M.C., Redondo M., Pascal M., Martin-Antonio B., Juan M., Urbano-Ispizua A., Rodriguez-Otero P., Alfonso-Pierola A., Paiva B., Lasarte J.J., Inoges S., Lopez-Diaz de Cerio A., San-Miguel J., de Larrea C.F., Hernaez M., Rodriguez-Madoz J.R., Prosper F.. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome. Science Advances. September 2022. DOI: 10.1126/sciadv.abo0514.
Impacto: 13.6. Cuartil: Q1
(1er decil)
Battram A.M., Oliver-Caldés A., Suárez-Lledó M., Lozano M., Bosch i Crespo M., Martínez-Cibrián N., Cid J., Moreno D.F., Rodríguez-Lobato L.G., Urbano-Ispizua A., Fernández de Larrea C.. T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells. Molecular Therapy Methods and Clinical Development. 8 September 2022. DOI: 10.1016/j.omtm.2022.06.010.
Pedrosa L., Foguet C., Oliveres H., Archilla I., de Herreros M.G., Rodríguez A., Postigo A., Benítez-Ribas D., Camps J., Cuatrecasas M., Castells A., Prat A., Thomson T.M., Maurel J., Cascante M.. A novel gene signature unveils three distinct immune-metabolic rewiring patterns conserved across diverse tumor types and associated with outcomes. Frontiers in Immunology. 2 September 2022. DOI: 10.3389/fimmu.2022.926304.
Impacto: 7.3. Cuartil: Q1
Crespo I., Pignatelli J., Kinare V., Méndez-Gómez H.R., Esgleas M., Román M.J., Canals J.M., Tole S., Vicario C.. Tbr1 Misexpression Alters Neuronal Development in the Cerebral Cortex. Molecular Neurobiology. September 2022. DOI: 10.1007/s12035-022-02936-x.
Impacto: 5.1. Cuartil: Q2
Jiménez-Segura R., Rosiñol L., Cibeira M.T., Fernández de Larrea C., Tovar N., Rodríguez-Lobato L.G., Bladé E., Moreno D.F., Oliver-Caldés A., Bladé J.. Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution. Blood Cancer Journal. September 2022. DOI: 10.1038/s41408-022-00730-5.
Impacto: 12.8. Cuartil: Q1
(1er decil)
Salas M.Q., Charry P., Pedraza A., Martínez-Cibrian N., Solano M.T., Domènech A., Suárez-Lledó M., Nomdedeu M., Cid J., Lozano M., de-LLobet N., Arcarons J., Rosiñol L., Gutiérrez-García G., Carreras E., Esteve J., Urbano-Ispizua Á., Fernández-Avilés F., Rovira M., Martínez C.. PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT. Transplantation and Cellular Therapy. August 2022. DOI: 10.1016/j.jtct.2022.05.009.
Impacto: 3.2. Cuartil: Q2
Oliva J., Pacini S., Canals J.M., Lim M.. Editorial: Mesenchymal Stromal Cells: Preclinical and Clinical Challenges. Frontiers in Cell and Developmental Biology. 18 July 2022. DOI: 10.3389/fcell.2022.969178.
Impacto: 5.5. Cuartil: Q1
Bueno C., Barrera S., Bataller A., Ortiz-Maldonado V., Elliot N., O'Byrne S., Wang G., Rovira M., Gutierrez-Agüera F., Trincado J.L., González-González M., Morgades M., Sorigué M., Bárcena P., Zanetti S.R., Torrebadell M., Vega-Garcia N., Rives S., Mallo M., Sole F., Mead A.J., Roberts I., Thongjuea S., Psaila B., Juan M., Delgado J., Urbano-Ispizúa A., Ribera J.M., Orfao A., Roy A., Menendez P.. CD34<sup>+</sup>CD19<sup>−</sup>CD22<sup>+</sup> B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. Blood. 7 July 2022. DOI: 10.1182/blood.2021014840.
Impacto: 20.3. Cuartil: Q1
(1er decil)
Oliver-Caldes A., Soler-Perromat J.C., Lozano E., Moreno D., Bataller A., Mozas P., Garrote M., Setoain X., Aróstegui J.I., Yagüe J., Tovar N., Jiménez R., Rodríguez-Lobato L.G., Cibeira M.T., Rosiñol L., Bladé J., Juan M., Fernández de Larrea C.. Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma. Frontiers in Oncology. 5 July 2022. DOI: 10.3389/fonc.2022.936993.
Impacto: 4.7. Cuartil: Q2
Cuadrado-Vilanova M., Liu J., Paco S., Aschero R., Burgueño V., Sirab N., Pascual-Pasto G., Correa G., Balaguer-Lluna L., Castillo-Ecija H., Perez-Jaume S., Muñoz-Aznar O., Roldan M., Suñol M., Schaiquevich P., Aerts I., Doz F., Cassoux N., Lubieniecki F., Benitez-Ribas D., Lavarino C., Mora J., Chantada G.L., Catala-Mora J., Radvanyi F., Carcaboso A.M.. Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients. Journal of Pathology. July 2022. DOI: 10.1002/path.5893.
Impacto: 7.3. Cuartil: Q1
(1er decil)
Molina-Ruiz F.J., Introna C., Bombau G., Galofre M., Canals J.M.. Standardization of Cell Culture Conditions and Routine Genomic Screening under a Quality Management System Leads to Reduced Genomic Instability in hPSCs. Cells. July-1 2022. DOI: 10.3390/cells11131984.
Impacto: 6.0. Cuartil: Q2
Ortiz-Maldonado V., Alonso-Saladrigues A., Español-Rego M., Martínez-Cibrián N., Faura A., Magnano L., Català A., Benítez-Ribas D., Giné E., Díaz-Beyá M., Correa J.G., Rovira M., Montoro-Lorite M., Martínez-Roca A., Rodríguez-Lobato L.G., Cabezón R., Cid J., Lozano M., Garcia-Rey E., Conde N., Pedrals G., Rozman M., Torrebadell M., Setoain X., Rodríguez S., Esteve J., Pascal M., Urbano-Ispizua Á., Juan M., Delgado J., Rives S.. Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease. American Journal of Hematology. 1 June 2022. DOI: 10.1002/ajh.26519.
Impacto: 12.8. Cuartil: Q1
(1er decil)
Moreno-Castaño A.B., Palomo M., Torramadé-Moix S., Martinez-Sanchez J., Ramos A., Molina P., Pino M., Gómez-Ramírez P., Bonastre L., Solano M.T., Escolar G., Rovira M., Rodríguez-Lobato L.G., Gutiérrez-García G., Carreras E., Fernández-Avilés F., Diaz-Ricart M.. An endothelial proinflammatory phenotype precedes the development of the engraftment syndrome after autologous Hct. Bone Marrow Transplantation. May 2022. DOI: 10.1038/s41409-022-01610-z.
Impacto: 4.8. Cuartil: Q1
Rosser A.E., Busse M.E., Gray W.P., Badin R.A., Perrier A.L., Wheelock V., Cozzi E., Martin U.P., Salado-Manzano C., Mills L.J., Drew C., Goldman S.A., Canals J.M., Thompson L.M.. Translating cell therapies for neurodegenerative diseases: Huntington's disease as a model disorder. Brain. 1 May 2022. DOI: 10.1093/brain/awac086.
Impacto: 14.5. Cuartil: Q1
(1er decil)
Roncador G., Puñet-Ortiz J., Maestre L., Rodríguez-Lobato L.G., Jiménez S., Reyes-García A.I., García-González Á., García J.F., Piris M.Á., Montes-Moreno S., Rodríguez-Justo M., Mena M.P., de Larrea C.F., Engel P.. CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma. Cancers. May-1 2022. DOI: 10.3390/cancers14092154.
Impacto: 5.2. Cuartil: Q2
Garcia-Prieto C.A., Villanueva L., Bueno-Costa A., Davalos V., González-Navarro E.A., Juan M., Urbano-Ispizua Á., Delgado J., Ortiz-Maldonado V., Del Bufalo F., Locatelli F., Quintarelli C., Sinibaldi M., Soler M., Castro De Moura M., Ferrer G., Urdinguio R.G., Fernandez A.F., Fraga M.F., Bar D., Meir A., Itzhaki O., Besser M.J., Avigdor A., Jacoby E., Esteller M.. Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies. Journal of the National Cancer Institute. 1 March 2022. DOI: 10.1093/jnci/djab194.
Impacto: 10.3. Cuartil: Q1
Bataller A., Garrido A., Guijarro F., Oñate G., Diaz-Beyá M., Arnan M., Tormo M., Vives S., de Llano M.P.Q., Coll R., Gallardo D., Vall-Llovera F., Escoda L., Garcia-Guiñon A., Salamero O., Sampol A., Merchan B.M., Bargay J., Castaño-Díez S., Esteban D., Oliver-Caldés A., Rivero A., Mozas P., López-Guerra M., Pratcorona M., Zamora L., Costa D., Rozman M., Nomdedéu J.F., Colomer D., Brunet S., Sierra J., Esteve J.. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Advances. 22 February 2022. DOI: 10.1182/bloodadvances.2021005585.
Impacto: 7.5. Cuartil: Q1
Urbano-Ispizua A., Hudecek M.. CART initiatives in Europe. The EBMT/EHA CAR-T Cell Handbook. 7 February 2022. DOI: 10.1007/978-3-030-94353-0_5.
Rodríguez-Lobato L.G., Pereira A., Fernández de Larrea C., Cibeira M.T., Tovar N., Jiménez-Segura R., Moreno D.F., Oliver-Caldés A., Rosiñol L., Bladé J.. Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period. British Journal of Haematology. February 2022. DOI: 10.1111/bjh.17888.
Impacto: 6.5. Cuartil: Q1
Trias E., Juan M., Urbano-Ispizua A., Calvo G.. The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001. Bone Marrow Transplantation. February 2022. DOI: 10.1038/s41409-021-01463-y.
Impacto: 4.8. Cuartil: Q1
Ghorashian S., Malard F., Yüksel M.K., Mauff K., Hoogenboom J.D., Urbano-Ispizua A., Kuball J., de la Camara R., Ljungman P., Ruggeri A., Chabannon C.. Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT. Bone Marrow Transplantation. February 2022. DOI: 10.1038/s41409-021-01483-8.
Impacto: 4.8. Cuartil: Q1
Ortiz-Maldonado V., Frigola G., Español-Rego M., Balagué O., Martínez-Cibrián N., Magnano L., Giné E., Pascal M., Correa J.G., Martínez-Roca A., Cid J., Lozano M., Villamor N., Benítez-Ribas D., Esteve J., López-Guillermo A., Campo E., Urbano-Ispizua Á., Juan M., Delgado J.. Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation. Frontiers in Oncology. 31 January 2022. DOI: 10.3389/fonc.2022.828471.
Impacto: 4.7. Cuartil: Q2
Oliver-Caldes A., Jiménez R., Español-Rego M., Cibeira M.T., Ortiz-Maldonado V., Quintana L.F., Castillo P., Guijarro F., Tovar N., Montoro M., Benitez-Ribas D., Bataller A., González-Navarro E.A., Cid J., Lozano M., Perez-Amill L., Martin-Antonio B., Mena M.P., Moreno D.F., Rodríguez-Lobato L.G., Campistol J.M., Calvo G., Bladé J., Rosiñol L., Juan M., Pascal M., Urbano-Ispizua A., Fernández De Larrea C.. First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma. Journal for ImmunoTherapy of Cancer. 7 December 2021. DOI: 10.1136/jitc-2021-003783.
Impacto: 12.469. Cuartil: Q1
(1er decil)
Ortiz-Maldonado V., Rives S., Español-Rego M., Alonso-Saladrigues A., Montoro M., Magnano L., Giné E., Pascal M., Diáz-Beyá M., Castella M., Català A., Faura A., Rodríguez-Lobato L.G., Oliver-Caldes A., Martínez-Roca A., Rovira M., González-Navarro E.A., Ortega J.R., Cid J., Lozano M., Garcia-Rey E., Fernández S., Castro P., Jordan I., Villamor N., Aymerich M., Torrebadell M., Deyà À., De Larrea C.F., Benitez-Ribas D., Trias E., Varea S., Calvo G., Esteve J., Urbano-Ispizua A., Juan M., Delgado J.. Factors associated with the clinical outcome of patients with relapsed/refractory CD19 + acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. Journal for ImmunoTherapy of Cancer. 1 December 2021. DOI: 10.1136/jitc-2021-003644.
Impacto: 12.469. Cuartil: Q1
(1er decil)
Spanjaart A.M., Ljungman P., de La Camara R., Tridello G., Ortiz-Maldonado V., Urbano-Ispizua A., Barba P., Kwon M., Caballero D., Sesques P., Bachy E., Di Blasi R., Thieblemont C., Calkoen F., Mutsaers P., Maertens J., Giannoni L., Nicholson E., Collin M., Vaz C.P., Metafuni E., Martinez-Lopez J., Dignan F.L., Ribera J.M., Nagler A., Folber F., Sanderson R., Bloor A., Ciceri F., Knelange N., Ayuk F., Kroger N., Kersten M.J., Mielke S.. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia. December 2021. DOI: 10.1038/s41375-021-01466-0.
Impacto: 12.883. Cuartil: Q1
(1er decil)
Isola I., Moreno D.F., Moga E., Mena M.P., Tovar N., Rodríguez-Lobato L.G., Oliver-Caldés A., Salgado M.C., Brasó-Maristany F., Yagüe J., Cibeira M.T., Prat A., Rosiñol L., Bladé J., Fernández de Larrea C.. Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. Annals of Hematology. December 2021. DOI: 10.1007/s00277-021-04653-2.
Impacto: 4.03. Cuartil: Q2
Isola I., Brasó-Maristany F., Moreno D.F., Mena M.P., Oliver-Calders A., Paré L., Rodríguez-Lobato L.G., Martin-Antonio B., Cibeira M.T., Bladé J., Rosiñol L., Prat A., Lozano E., Fernández de Larrea C.. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. Frontiers in Immunology. 22 November 2021. DOI: 10.3389/fimmu.2021.792609.
Impacto: 8.786. Cuartil: Q1
Leal L., Couto E., Sánchez-Palomino S., Climent N., Fernández I., Miralles L., Romero Y., González T., Maleno M.J., Paño B., Pich J., Nicolau C., Gatell J.M., Plana M., García F., Hurtado C., Burunat L., Arnaiz J.A., Salvador R., Farré E., Torres B., Lucero C., Laguno M., Martínez-Rebollar M., González-Cordón A., Rojas J., Inciarte A., de la Mora L., Mallolas J., Martínez E., Blanco J.L., Perpiñá U., Canals J., Martín R., Echeverry F., Xufré C., Rovira C., Sala M., Tricas A.. Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial. Frontiers in Immunology. 11 November 2021. DOI: 10.3389/fimmu.2021.767370.
Impacto: 8.786. Cuartil: Q1
Juan M., Delgado J., Calvo G., Trias E., Urbano-Ispizua Á.. Is Hospital Exemption an Alternative or a Bridge to European Medicines Agency for Developing Academic Chimeric Antigen Receptor T-Cell in Europe? Our Experience with ARI-0001. Human Gene Therapy. October 2021. DOI: 10.1089/hum.2021.168.
Impacto: 4.793. Cuartil: Q1
Bayó C., Jung G., Español-Rego M., Balaguer F., Benitez-Ribas D.. Vaccines for non-viral cancer prevention. International Journal of Molecular Sciences. October-2 2021. DOI: 10.3390/ijms222010900.
Impacto: 6.208. Cuartil: Q1
Bartoló-Ibars A., Uribe-Herranz M., Muñoz-Sánchez G., Arnaldos-Pérez C., Ortiz-Maldonado V., Urbano-Ispizua Á., Pascal M., Juan M.. Car-t after stem cell transplantation in b-cell lymphoproliferative disorders: Are they really autologous or allogenic cell therapies?. Cancers. 2 September 2021. DOI: 10.3390/cancers13184664.
Impacto: 6.575. Cuartil: Q1
Bachiller M., Perez-Amill L., Battram A.M., Carné S.C., Najjar A., Verhoeyen E., Juan M., Urbano-Ispizua A., Martin-Antonio B.. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness. Journal for ImmunoTherapy of Cancer. 25 August 2021. DOI: 10.1136/jitc-2021-002866.
Impacto: 12.469. Cuartil: Q1
(1er decil)
Bruno B., Wäsch R., Engelhardt M., Gay F., Giaccone L., D’Agostino M., Rodríguez-Lobato L.G., Danhof S., Gagelmann N., Kröger N., Popat R., Van De Donk N.W.C.J., Terpos E., Dimopoulos M.A., Sonneveld P., Einsele H., Boccadoro M.. European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma. Haematologica. August 2021. DOI: 10.3324/haematol.2020.276402.
Impacto: 11.047. Cuartil: Q1
(1er decil)
Battram A.M., Bachiller M., Lopez V., de Larrea C.F., Urbano-Ispizua A., Martín-Antonio B.. Il-15 enhances the persistence and function of bcma-targeting car-t cells compared to il-2 or il-15/il-7 by limiting car-t cell dysfunction and differentiation. Cancers. 2 July 2021. DOI: 10.3390/cancers13143534.
Impacto: 6.575. Cuartil: Q1
Martínez-Roca A., Rodríguez-Lobato L.G., Ballestar N., Gallego C., Fernández-Avilés F.. Personalized at-home autologous hematopoietic stem cell transplantation during the SARS-CoV-2 outbreak. Leukemia Research. July 2021. DOI: 10.1016/j.leukres.2021.106589.
Impacto: 3.715. Cuartil: Q3
Pedraza A., Jorge S., Suárez-Lledó M., Pereira A., Gutiérrez-García G., Fernández-Avilés F., Rosiñol L., Llobet N., Solano T., Urbano-Ispízua Á., Rovira M., Martínez C.. High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation. Transplantation and Cellular Therapy. July 2021. DOI: 10.1016/j.jtct.2021.03.022.
Impacto: 0.0. Cuartil: N/D
Puerta-Alcalde P., Chumbita M., Charry P., Castaño-Díez S., Cardozo C., Moreno-García E., Marco F., Suárez-Lledó M., Garcia-Pouton N., Morata L., Fernández-Avilés F., Martínez-Roca A., Rodríguez G., Martínez J.A., Martínez C., Mensa J., Urbano Á., Rovira M., Soriano A., Garcia-Vidal C.. Risk Factors for Mortality in Hematopoietic Stem Cell Transplantation Recipients with Bloodstream Infection: Points To Be Addressed by Future Guidelines. Transplantation and Cellular Therapy. June 2021. DOI: 10.1016/j.jtct.2021.03.017.
Impacto: 0.0. Cuartil: N/D